The role of newer monoclonal antibodies in renal transplantation.

@article{Vincenti2001TheRO,
  title={The role of newer monoclonal antibodies in renal transplantation.},
  author={Flavio G Vincenti},
  journal={Transplantation proceedings},
  year={2001},
  volume={33 1-2},
  pages={
          1000-1
        }
}
  • F. Vincenti
  • Published 2001
  • Medicine
  • Transplantation proceedings
BIOLOGIC agents have been used in transplantation in the prophylaxis of rejection, in the induction phase of therapy, and in the reversal of acute rejection, especially steroid-resistant or vascular-type rejection. Historically, two biologic agents have been used: the polyclonal antilymphocyte agents and the murine monoclonal antibody (MAb) anti-CD3, OKT3. Although effective, these agents are associated with many side effects. The newer generation of humanized antibodies (also chimeric) have… Expand
Induction Therapy in Renal Transplantation
TLDR
What has resulted during the past 20 years as the use of induction agents has become more popular is the concurrent improvement in detection and treatment of acute and chronic infectious, and opportunistic and quasi-malignant disease accompanying theuse of these agents and, therefore, their increase in popularity. Expand
New developments in immunosuppressive therapy in renal transplantation
TLDR
In the presence of low early rejection rates, immunosuppressive therapy is setting new goals such as better graft function, reduction in adverse effects such as hypertension, hyperlipidaemia and drug toxicity and, above all, the prevention of late graft deterioration. Expand
The role of basiliximab induction therapy in organ transplantation
TLDR
Basiliximab induction therapy given at days 0 and 4 after transplantation appears to be safe and cost-effective for immunoprophylaxis in solid organ transplant recipients, specifically in kidney and liver transplantation, when given in conjunction with dual or triple immunosuppressive therapy. Expand
Immunosuppression: towards a logical approach in liver transplantation
TLDR
The mechanism of action of drugs is outlined and possible approaches to the management of the liver allograft recipient are suggested, suggesting how treatment could be adjusted according to the indication for transplantation as well as the individual's comorbidities. Expand
Immunosuppression minimization in kidney transplantation.
TLDR
It seems possible and safe to avoid corticosteroids and/or calcineurin inhibitors in many patients, and the application of protocol biopsies as well as new immunological tests to determine the degree of immunosuppression will certainly help transplant physicians to provide more personalized treatment strategies. Expand
New Insights Into the Interactions Between T-Cell Costimulatory Blockade and Conventional Immunosuppressive Drugs
TLDR
Sufficient costimulatory blockade and synergy induced by CD154 blockade and rapamycin promote allograft tolerance and prevent chronic rejection and the widespread view that calcineurin inhibitors abrogate the effects of T-cell costimulations should be revisited. Expand
Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long‐term kidney graft outcomes
  • D. Baron, M. Giral, S. Brouard
  • Medicine
  • Transplant international : official journal of the European Society for Organ Transplantation
  • 2015
TLDR
The identification of patients, harbouring these markers, among immunosuppressed recipients with stable graft function and the existence of drugs with selective effect on B cell pave the way for the possibility to improve long‐term graft outcomes. Expand
Basiliximab Induction Therapy in Organ Transplantation
TLDR
In pediatric renal and liver transplantation recipients, Basiliximab clearance is independent of age, weight, and body surface area. Expand
Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients
TLDR
Daclizumab was associated with a significantly reduced risk for rejection and graft loss compared with no induction treatment, and improved patient survival, and was not associated with an increase in risk of death due to infection or malignancy, when compared withno induction therapy. Expand
Immunosuppression minimization: current and future trends in transplant immunosuppression.
  • F. Vincenti
  • Medicine
  • Journal of the American Society of Nephrology : JASN
  • 2003
The past decade has witnessed unprecedented advances in renal transplantation propelled by novel and effective immunosuppression drugs. The introduction of mycophenolate mofetil (MMF), tacrolimus,Expand
...
1
2
...

References

SHOWING 1-4 OF 4 REFERENCES
Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression.
TLDR
During the early posttransplant period anti-CD25 monoclonal antibodies combined with rapamycin and steroids offer a promising baseline therapy to avoid cyclosporine exposure and facilitate recovery from ischemic/reperfusion injuries. Expand
Specific suppression of interleukin 2 biosynthesis by synthetic antisense oligodeoxynucleotides does not influence allograft rejection.
TLDR
Antisense oligonucleotides can powerfully suppress IL-2 biosynthesis in vitro and in allograft recipients in vivo, but this does not affect kidney allografted rejection. Expand